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Methods and Results
Changes in diameter were assessed in 224 coronary stenoses of 92 consecutive patients (62 men) with chronic stable angina pectoris who were on a waiting list for routine coronary angioplasty and underwent coronary angiography on two occasions: the first (diagnostic) angiogram was carried out at study entry and the second 5·5 3·0 months later, immediately prior to coronary angioplasty. A digital quantitative angiographic analysis system was used to assess differences in stenosis diameter between the first and second angiogram. Plasma immunoreactive endothelin levels were estimated by radioimmunoassy at study entry. Rapid coronary artery disease progression occurred in 29 (31·5%) patients according to pre-established criteria: 12 (41%) had a d10% diameter reduction of at least one pre-existing stenosis d50%, 10 (34%) had a d30% diameter reduction of a pre-existing stenosis <50%, 5 (17%) patients developed a new stenosis and 2 (7%) had progression of a lesion to total occlusion by the second angiogram. Baseline demographic, clinical and angiographic data were similar in patients with and without stenosis progression. Plasma endothelin levels were significantly higher in patients with rapid disease progression than in those without (5·7 2·0 pg . ml 1 vs 3·9 1·6 pg . ml 1 , P<0·001) . Multiple logistic regression analysis revealed that endothelin was an independent predictor of disease progression (P=0·001). Moreover, endothelin levels above 4·26 pg . ml 1 (the median of the total endothelin concentrations) were associated with a sixfold increase in the risk of developing rapid stenosis progression.
Introduction
Rapid coronary artery disease progression leading to coronary artery occlusion and/or acute coronary events is unpredictable [1] [2] [3] [4] and does not appear to be associated with stenosis severity [5, 6] . Although coronary stenosis progression is influenced by both local and systemic factors [7, 8] the precise mechanisms underlying this process remain elusive. In recent years it has become apparent that inflammatory mechanisms involved in the atherogenic process may lead to plaque disruption, stenosis progression and acute coronary syndromes [9] . Studies [10] have shown that subclinical episodes of fissuring and disruption of 'active' atheromatous plaques, with local thrombin activation and subsequent healing, may represent a pathway for coronary artery disease progression. Accelerated proliferation of cells in the vascular wall may also play a significant role in this process [11] . Endothelins are a family of potent vasoconstrictor peptides [12] which have cell growth-promoting and mitogenic properties [13, 14] . Plasma endothelin has been found to be increased in patients with advanced atherosclerosis [15] and we have previously shown that plasma endothelin levels are significantly associated with both the extent and severity of coronary artery disease [16] . Moreover, endothelin-1 has been implicated in the inflammatory process taking place in active atheromatous coronary lesions associated with acute coronary syndromes [17] . In this study, we sought to investigate the association between plasma endothelin levels and rapid coronary artery disease progression in patients with chronic stable angina pectoris.
Methods

Study population
We studied 92 patients (62 men and 30 women) with chronic stable angina pectoris awaiting routine coronary angioplasty. Patients included in this study formed part of a larger cohort of 128 consecutive patients who underwent diagnostic coronary angiography in our institution in the first trimester of 1998 and were considered to be candidates for non-urgent coronary angioplasty. Patients with previous coronary bypass surgery, myocardial infarction -as defined by standard WHO criteria -in the previous 3 months, clinically significant valvular heart disease, serious conduction disturbances, heart failure, significant arrhythmias, history of renal, liver or metabolic disease and patients whose angiograms were not suitable for computerized analysis were excluded from the study (n=36). The 92 patients included in the study had been on the waiting list for at least 3 and up to 12 months (mean time: 5·5 3·0 months) from the time of diagnostic coronary angiography. All patients gave written informed consent and the study was approved by the local ethics committee.
Coronary angiographic analysis
As part of the standardized evaluation of patients on the waiting list, all 92 patients prospectively underwent coronary angiography on two occasions: the first (diagnostic) angiogram was carried out at study entry and the second immediately prior to coronary angioplasty. The study protocol for the assessment of rapid coronary artery disease progression in patients on waiting lists in our institution has been described previously [18, 19] . Briefly, diagnostic arteriograms were carried out using standard methods and standardized projections, which were recorded and reproduced at the time of the second angiogram. All patients fasted overnight and were asked not to smoke in the 12 h before catheterization. Medical therapy was not discontinued. Sublingual glyceryltrinitrate (0·5 mg) was administered 2 to 5 min before contrast injection at both the first and the second angiogram to all patients to minimize the effect of vasomotor tone on the coronary lumen diameter size. Angiographic data were acquired on a digital system (Philips Integris HM3000) incorporating a software package validated for quantitative angiography.
Each pair of coronary angiograms were quantitatively assessed by two independent observers blinded to the identity and clinical characteristics of the patients. Angiograms were analysed in random order. Paired angiograms in each individual patient were analysed at different sessions and not in succession. To assess intraand inter-observer variability, 10 randomly selected pairs of angiograms were reviewed by both observers independently and by the same observer twice, on two different occasions, some time apart. Differences in stenosis diameter between the first and second angiogram were assessed in 29 stenoses. Intra-and interobserver variability for stenosis diameter changes between angiograms were estimated at 3·8 1·8% and 4·4 2·1, respectively. The 95% limits of agreement were 0·2 to 7·7% and 0·2 to 8·6%, respectively.
A stenosis d50% diameter reduction was considered significant and a lesion <50% was considered mild. The methods used to quantitatively measure coronary artery diameters has been reported in detail previously [18, 19, 21] . Briefly, the stem of the Judkins coronary catheter was used for calibration to determine absolute measurements in millimetres and correction was made for radiographic pincushion distortion. For each segment, measurements were carried out on end-diastolic frames, where the severity of the stenoses appeared maximal. Percent diameter reduction of a coronary stenosis was calculated by comparing the minimal stenosis diameter to the diameter of the reference segment (an angiographically normal segment proximal to the lesion) measured in millimetres. The following formula was used: % diameter reduction=[(diameter or reference segmentdiameter of stenosis)/diameter of reference segment] 100. Rapid coronary artery disease progression was defined as: (1) d10% diameter reduction of a pre-existing stenosis d50%, (2) d30% diameter reduction of a pre-existing stenosis <50%, (3) progression of any lesion to total occlusion at the second angiogram, (4) 'new' lesions were a diameter reduction d30% in a segment that was normal at the first angiogram.
Cardiac events
After the first angiogram, patients were followed at regular intervals while they were on the waiting list and the following clinical events were recorded: (1) hospital admission with Braunwald's class IIIb unstable angina, (primary rest angina within 48 h prior to admission) [22] , requiring i.v. treatment and/or coronary revascularization, (2) myocardial infarction, defined according to WHO criteria; and (3) cardiac death.
Endothelin measurement
Venous blood samples were collected from the antecubital vein from all patients at study entry and after a
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20-min period of supine rest. In 15 randomly selected patients, blood sampling was repeated at the time of the second angiogram in order to assess changes in endothelin levels during follow-up. Blood was drawn into chilled citrate tubes on ice and plasma was separated by centrifugation at 1500 g for 10 min at 4 C. Plasma immunoreactive endothelin concentrations were estimated by radioimmunoassay (Nichols Institute, Diagnostic B.V., Wychen, Netherlands) as previously described [23] . The sensitivity of the assay was 2 pg . ml 1 , with 100% cross-reactivity with endothelin-1, 52% with endothelin-2, 96% for endothelin-3 and 7% for big endothelin. Cross-reactivity with atrial natriuretic peptide, angiotensin II, adrenocorticotropic hormone and vasopressin was <0·1%. The inter-assay variability was <10%.
Statistical analysis
Results are presented as mean 1 standard deviation (SD) for continuous variables and as percentages for categorical data. Analysis of normality was performed with the Kolmogorov-Smirnov test. Comparisons between patient groups were performed by use of the two-tailed t-test for unpaired observations or the MannWhitney U test as appropriate. Differences between repeated measurements were assessed by a paired twotailed t-test. Categorical data and proportions were analysed using Chi-square or Fisher's exact test when required. We assessed independent predictors for disease progression using logistic regression analysis, where the dependent variable was coronary artery disease progression and the independent variables were endothelin, coronary artery disease risk factors (smoking, diabetes, hypertension, hyperlipidaemia, family history), treatment with lipid lowering agents as well as levels of glucose, total and LDL cholesterol. A P value <0·05 was considered statistically significant. The SPSS 8.0 statistical software package (SPSS Inc, Illinois, U.S.A.) was used for all calculations.
Results
During 5·5 3·0 months (range: 3 to 12 months) coronary artery disease progression occurred in 29 (31·5%) of the 92 patients according to the pre-established criteria. Demographic and clinical data of patients with (Group A) and those without (Group B) rapid disease progression are presented on Table 1 . There were no significant differences in risk factors, history of myocardial infarction, or medication and biochemical values between the two groups. During the time on the waiting list, there was no significant modification in the patients' treatment. Repeated measurements (at the time of the 
Coronary angiography
We analysed a total of 224 lesions (mean 2·4 per patient); 117 (52%) were located in the left anterior descending artery and its branches, 52 (23%) in the circumflex coronary artery and 55 (25%) in the right coronary artery. Of the 29 patients fulfilling the preestablished criteria for coronary artery disease progression, 12 (41%) had a d10% diameter reduction of at least one pre-existing stenosis d50%, 10 (34%) had a d30% diameter reduction of a pre-existing stenosis <50%, 5 (17%) patients developed a new stenosis and 2 (7%) had progression of a lesion to total occlusion at the second angiogram. Baseline coronary artery disease severity, stenoses location as well as the time elapsed between the two angiograms was similar in the two groups ( Table 2 ). The baseline angiographic characteristics of patients with (Group A) or without (Group B) coronary artery disease progression are presented in Table 2 .
Plasma endothelin
Plasma endothelin levels were significantly higher in patients with rapid coronary artery disease progression than in those without (5·7 2·0 pg . ml 1 vs 3·9 1·6 pg . ml 1 , P<0·001, Fig. 1 ). When logistic regression analysis was used to assess independent Rapid CAD progression Plasma endothelin (pg.ml 
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predictors for disease progression, among the variables which were tested (endothelin, coronary artery disease risk factors, treatment with lipid lowering agents, levels of glucose, total and LDL cholesterol) only endothelin was found to be an independent predictor of rapid disease progression (P=0·001; Chi-square of the model=29·1, P=0·006). When the median of the total endothelin distribution (4·26 pg . ml 1 ) was used as a cut-off point we found that concentrations of endothelin above that level were associated with a significant sixfold increase in the risk of developing coronary artery disease progression (odds ratio: 6·6, 95% confidence interval: 2·3-18·7, P<0·001).
There were no significant differences in plasma endothelin levels between the first and second measurement in 15 randomly selected patients in whom repeat endothelin plasma levels were assessed at the time of the second angiographic study (4·2 1·9 pg . ml 1 vs 3·9 1·7 pg . ml 1 , P=0·49). Baseline plasma endothelin levels were similar in patients with and without diabetes, hyperlipidaemia, hypertension and a family history of coronary artery disease, as well as in smokers and non-smokers. Body mass index did not differ in patients with high endothelin levels compared to those with low endothelin levels.
Discussion
As in previous studies of rapid coronary artery disease progression from our group [5, 18, 19] , in this investigation we took advantage of the waiting list for routine coronary angioplasty existing in our institution at the time of the study. We prospectively studied the evolution of over 200 coronary artery stenoses in 92 consecutive patients with chronic stable angina pectoris who were awaiting coronary angioplasty. Our results showed that plasma endothelin was significantly increased in patients with rapid stenosis progression compared to those without. To our knowledge, this is the first study, to report an independent association of endothelin levels with the rapid progression of coronary artery disease. Our results also provide further support to previous suggestions by Lerman et al. [15] and our own previous findings [16] , that plasma endothelin levels correlate with both the occurrence and severity of atherosclerotic disease. Moreover, the present results are also in agreement with findings of Zeiher et al. [17] in patients with unstable angina. These authors observed a correlation between endothelin expression and atheromatous plaque activity.
Stenosis progression
A number of studies from our group [18, 19] and others [1] [2] [3] have shown that the rate of progression of atherosclerotic lesions varies from patient to patient. Moreover, within patients, individual plaques may differ in their rate of growth [19] . Coronary lesions appear to have an episodic rather than a linear progression with time [1] [2] [3] [4] 24, 25] and rapid coronary artery disease progression leading to total coronary artery occlusion does not necessarily occur in severe stenoses [5, 6, 19] . Mild coronary stenoses and even previously 'normal' coronary artery segments may develop new lesions within months or weeks, as observed in previous studies [26] and confirmed by the present study. Rapid coronary artery disease progression is likely to result from plaque disruption or endothelial erosion leading to intracoronary thrombosis. Studies have shown that minor subsidiary episodes of atheromatous plaque disruption and thrombosis are frequent in atherosclerotic disease [10, 11, [27] [28] [29] . Such episodes of 'active' plaque disruption with subsequent healing, in the absence of any clinical symptoms, have been suggested to be a major factor for coronary artery disease progression. In a recent pathological study in patients dying suddenly of ischaemic heart disease, Mann and Davies [10] reported that more than 70% of high grade coronary stenotic lesions had had an episode of prior disruption. This finding lends further support to the theory of healed disruption as a mechanism of coronary stenosis progression [11] . Moreover, it has been shown that accelerated proliferation of smooth muscle cells may accompany plaque disruption and thrombus formation [11] . A localized inflammatory process involving the infiltration of the arterial wall by activated macrophages and lymphocytes with increased expression of proinflammatory cytokines, metalloproteinases and procoagulant factors has been consistently shown to be associated with atheromatous plaque disruption [9, 30, 31] .
Endothelin and stenosis progression
Endothelin has several different biological effects and its role in rapid coronary artery disease progression is likely to be complex. Further to its vasocostrictor and mitogenic properties, endothelin appears to be involved in the inflammatory process that underlies 'active' atheromatous plaques [17] . Although still a matter of controversy [32] [33] [34] , studies have suggested that plasma endothelin is increased in patients with acute coronary syndromes [34] . Experimental studies have shown that endothelin may be produced by activated human macrophages [35] and has been also implicated in cytokine [36] and vascular cell adhesion molecule expression [37] . Zeiher et al. [17] , examined atherosclerotic tissue obtained by directional coronary atherectomy in 50 patients with coronary artery disease and showed an association of endothelin-1 immunoreactivity with coronary plaque components indicative of a chronic inflammatory process. Macrophage-rich areas, hypercellular areas showing neovascularization, and areas with evidence of previous intraplaque haemorrhage, were significantly associated with the presence of endothelin-1 [17] . Active plaques were found to have higher endothelin-1 staining grades than non-active ones and similarly patients with acute clinical syndromes were also shown to have significantly higher endothelin-1 staining grades than those with stable angina [17] . These findings, taken together, support the hypothesis that endothelin is involved in the inflammatory mechanisms that underlie the de-stabilization of an atheromatous lesion and may lead to its rupture. Such subclinical episodes of plaque disruption, in turn, may offer the substrate for the rapid progression of coronary lesions.
Accelerated proliferation of vascular cells may be a contributing mechanism for rapid coronary lesion progression [11, 38, 39] . Thrombus formation superimposed on plaque fissuring and disruption can promote a reparative proliferative response of the vascular wall [38, 39] .
Endothelin may potentiate such a process through its mitogenic and cell-growth properties. In support of this hypothesis, endothelin-1-like immunoreactivity has been observed in endothelial cells and vascular smooth muscle cells [15] and has been shown to stimulate DNA synthesis in cultured vascular smooth-muscle cells in a dose-dependent manner [13] . Importantly, studies have shown that DNA synthesis is inhibited by antiendothelin antibodies [14] . Our results thus suggest that endothelin may play a pathogenic role in rapid coronary artery disease progression. This is also supported by a recent experimental study by Barton and colleagues [40] who found that endothelin A receptor blockade in apolipoprotein E-Knockout mice resulted in a 30% decrease of aortic atherosclerotic lesions. The present study also shows that high plasma levels of endothelin, as detected in our patients with coronary stenosis progression, may be a marker of risk of rapid disease progression. Indeed, we observed that endothelin levels above 4·26 pg . ml 1 were associated with a sixfold increase in the risk of developing rapid stenosis progression. High endothelin levels may be a marker of endothelial cell injury, linked to the various stages of inflammatory and immune activity that underlie atheromatous plaque progression.
In this study we measured plasma immunoreactive endothelin levels, but this may not reflect the true production of endothelin by vascular wall cells. It is well established that endothelin is released abluminally and therefore levels measured in plasma presumably result from spillover from the interface of endothelial cells and vascular smooth-muscle cells. Although plasma endothelin levels appear to reflect the local concentration of the peptide, the true concentration of endothelin at the local site is likely to be significantly higher.
In a previous study [18] we have observed an association between rapid coronary artery disease progression and coronary artery stenosis morphology. In this study we did not specifically investigate the relationship between endothelin concentration and stenosis morphology as this issue has been already addressed in a recent study from our group [16] which showed that endothelin levels were similar in patients with complex and in those with smooth stenoses.
In agreement with previous reports [41] , we did not observe significant differences in family history, smoking behaviour, history of diabetes mellitus, hypertension and LDL cholesterol or triglycerides levels between patients with and without evidence of rapid coronary artery disease progression. This suggests that these traditional risk factors, although important in atherogenesis, may not necessarily play a decisive role in the process of rapid disease progression.
Conclusions
Plasma endothelin is significantly increased in patients with stable angina pectoris who develop rapid coronary stenosis progression compared to those without progression. This finding suggests both that endothelin may be a marker of rapid coronary artery disease progression and may also have a pathogenic role in this process. The use of the recently introduced endothelin receptor antagonists may help to investigate the clinical implications of the observations reported in this study.
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